Carisoprodol Urine with Reflex to Quantitation
Also known as: CARIS RFXU
Use
This test is useful for general screening in contexts of compliance and/or abuse. It is the preferred method for ruling out exposure to carisoprodol and/or meprobamate. Reflex testing is triggered by a positive screening result to confirm and quantify the presence of carisoprodol and its metabolite, meprobamate.
Special Instructions
Not provided.
Limitations
This test may not detect drug presence in cases of non-compliance, inappropriate timing of specimen collection, poor drug absorption, or diluted/adulterated urine. It is not valid for forensic use and the concentration required to detect a drug or metabolite varies within a drug class. Performance characteristics were determined by ARUP Laboratories, and the test is intended for clinical purposes.
New York Approved
Methodology
Immunoassay
Biomarkers
LOINC Codes
- 54247-2 - Drug screen comment Ur-Imp
- 21142-5 - Carisoprodol Ur Ql
Result Turnaround Time
1-6 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
4 mL
Minimum Volume
2 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Transfer urine with no additives or preservatives.
Storage Instructions
Refrigerated
Causes for Rejection
Breast milk, Pharmaceutical preparation, Specimens exposed to multiple freeze thaw cycles.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 1 month |
| Frozen | 1 month |
Other tests from different labs that may be relevant